JNJ Stock Recent News
JNJ LATEST HEADLINES
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
'Mad Money' host Jim Cramer revisits Johnson & Johnson's stock after a rough year for healthcare.
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $178.41, denoting a +1.49% move from the preceding trading day.
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor. 1
Johnson & Johnson (NYSE:JNJ ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Joaquin Duato - CEO & Chairman John Reed - Executive Vice President of Innovative Medicine, R&D Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.
The U.S. Food and Drug Administration has approved Johnson & Johnson's drug delivery system for patients with a type of bladder cancer, the drugmaker said on Tuesday, offering a potential alternative to surgically remove the organ.